Xu JM - Search Results

1

[Comparison of endocrine therapy and chemotherapy for bone metastasis of breast cancer].

Yan M, Song ST, Jiang ZF, Zhang SH, Liu XQ, Xu JM, Wang T, Luo WD. Yan M, et al. Among authors: xu jm. Zhonghua Zhong Liu Za Zhi. 2004 Mar;26(3):177-80. Zhonghua Zhong Liu Za Zhi. 2004. PMID: 15196443 Chinese.

2

[The effect of IRESSA on H22 mouse hepatocellular carcinoma].

Zhu BD, Yuan SJ, Xu JM, Zhao QC, Li X, Li Y, Hao LH. Zhu BD, et al. Among authors: xu jm. Zhonghua Yi Xue Za Zhi. 2004 Apr 17;84(8):684-6. Zhonghua Yi Xue Za Zhi. 2004. PMID: 15130315 Chinese.

3

[hTERT promoter regulated replication-selective adenovirus CNHK300 in treatment of hepatocellular carcinoma].

Li YM, Song ST, Jiang ZF, Zhang Q, Su CQ, Xu JM, Qian YZ, Qian QJ. Li YM, et al. Among authors: xu jm. Zhonghua Yi Xue Za Zhi. 2005 Feb 23;85(7):468-72. Zhonghua Yi Xue Za Zhi. 2005. PMID: 15854553 Chinese.

4

[Prognostic value of thymidylate synthase, topoisomerase-1 and Ki-67 in advanced colorectal cancer patients on irinotecan and fluorouracil treatment].

Xu JM, Zhu BD, Mangia A, Simone G, Montemurro S, Giuliani F, Maiello E, Colucci G, Paradiso A. Xu JM, et al. Zhonghua Zhong Liu Za Zhi. 2005 May;27(5):312-5. Zhonghua Zhong Liu Za Zhi. 2005. PMID: 15996331 Chinese.

5

[Current status of the study of the mechanism of epidermal growth factor receptor targeting drug therapy and their related markers].

Wang Y, Xu JM, Song ST. Wang Y, et al. Among authors: xu jm. Zhonghua Zhong Liu Za Zhi. 2005 Sep;27(9):573-6. Zhonghua Zhong Liu Za Zhi. 2005. PMID: 16438862 Chinese. No abstract available.

6

Phase II trial of sequential gefitinib after minor response or partial response to chemotherapy in Chinese patients with advanced non-small-cell lung cancer.

Xu JM, Han Y, Li YM, Zhao CH, Wang Y, Paradiso A. Xu JM, et al. BMC Cancer. 2006 Dec 16;6:288. doi: 10.1186/1471-2407-6-288. BMC Cancer. 2006. PMID: 17173694 Free PMC article. Clinical Trial.

7

[Experimental study of effect of epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in combination with irinotecan].

Xu JM, Li YM, Wang Y, Zhao CH, Yuan SJ, Yang WW, Li ZQ, Han Y, Azzariti A, Paradiso A. Xu JM, et al. Zhonghua Zhong Liu Za Zhi. 2006 Aug;28(8):578-82. Zhonghua Zhong Liu Za Zhi. 2006. PMID: 17236550 Chinese.

8

[Safety and efficacy of gefitinib for treatment of advanced non-small cell lung cancer].

Xu JM, Li YM, Liu XQ, Zhang Y, Han Y, Yang WW, Song ST. Xu JM, et al. Zhonghua Zhong Liu Za Zhi. 2007 Jan;29(1):66-9. Zhonghua Zhong Liu Za Zhi. 2007. PMID: 17575699 Clinical Trial. Chinese.

9

[EGFR mutation predicts response and prognosis in iressa-treated advanced-stage non-small cell lung cancer].

Han Y, Xu JM, Duan HQ, Song ST, Liu XQ, Zhang Y, Zhang JS. Han Y, et al. Among authors: xu jm. Zhonghua Zhong Liu Za Zhi. 2007 Apr;29(4):278-83. Zhonghua Zhong Liu Za Zhi. 2007. PMID: 17760255 Chinese.

10

[Cytotoxic effect of epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in combination with oxaliplatin on lung cancer cell line A549].

Zhao CH, Yuan SJ, Wang Y, Ge FJ, Luo WD, Xu JM. Zhao CH, et al. Among authors: xu jm. Ai Zheng. 2007 Dec;26(12):1299-303. Ai Zheng. 2007. PMID: 18076790 Free article. Chinese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

653 results

Search Page

Filters